
Nektar Therapeutics and Jonathan Zalevsky, PhD, are exploring REZPEG's potential in treating alopecia, atopic dermatitis, lupus, and diabetes, aiming for groundbreaking autoimmune therapies.

Nektar Therapeutics and Jonathan Zalevsky, PhD, are exploring REZPEG's potential in treating alopecia, atopic dermatitis, lupus, and diabetes, aiming for groundbreaking autoimmune therapies.

Nektar Therapeutics explores rezpegaldesleukin's potential as a groundbreaking treatment for alopecia areata, aiming for FDA approval and improved patient outcomes.

Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.

Jonathan Zalevsky, PhD, discusses the fundamentally different path of Rezpeg compared with existing IL-4 and IL-13 inhibitors in atopic dermatitis.

Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.

Published: February 18th 2025 | Updated:

Published: August 8th 2025 | Updated:

Published: February 17th 2025 | Updated:

Published: February 14th 2025 | Updated:

Published: August 11th 2025 | Updated: